Colesevelam (WelChol) oral suspension packets — Coverage and prior authorization criteria
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PMN.250 alerts
Get alerted when Policy MDN.CP.PMN.250 changes without checking for updates manually.
Monitor payer policy activity
Coverage and prior authorization criteria for WelChol (colesevelam) packets for suspension for Meridian Health Plan Medicaid members, including indications, age limits, required trials, and dosing limits.
No material clinical or coverage changes in this revision.
Coverage Criteria
COVERAGE CRITERIA
WelChol packet for suspension is covered when ALL of the following criteria for the specific indication are met.
Primary Hyperlipidemia Initial Approval
Request specifics
- Product: Request is for Welchol packet for suspension
- Indication: Prescribed for lipid lowering
- Age >= 10 years
- Swallowing/Tablet intolerance: Documentation supports inability to swallow pills or clinically significant adverse effects to Welchol tablets
- Cholestyramine trial: Failure of cholestyramine powder for suspension at up to maximally indicated doses, each used for >= 3 months, unless contraindicated or clinically significant adverse effects are experienced>= 3 months
- Statin trial: Failure of >= 3 consecutive months of adherent use of a statin therapy, unless contraindicated or clinically significant adverse effect are experienced>= 3 months
- Triglyceride limit: Current (within last 3 months) serum triglycerides do not exceed 500 mg/dL<= 500 mg/dL
- Dose limit: Dose does not exceed oral suspension packet of 3.75 grams (1 packet) per day<= 3.75 g/day
Type 2 Diabetes Mellitus Initial Approval
Request specifics
- Product: Request is for Welchol packet for suspension
- Diagnosis of type 2 diabetes mellitus
- Age >= 18 years
- HbA1c drawn within the past 3 months is >= 6.5%>= 6.5% within 3 months
- Triple anti-diabetic regimen failure: Failure of adherent use of a triple anti-diabetic regimen which must include metformin in combination with agents from listed classes (GLP-1 RA, SGLT-2 inhibitor, DPP-4 inhibitor, TZD, or basal insulin) for >= 3 months, unless clinically significant adverse effects or contraindications>= 3 months
metformin must be included
- Triglyceride limit: Current (within last 3 months) serum triglycerides do not exceed 500 mg/dL<= 500 mg/dL
- Dose limit: Dose does not exceed oral suspension packet of 3.75 grams (1 packet) per day<= 3.75 g/day
Other diagnoses/indications
- Recent label change: If drug had a label change within last 6 months not yet reflected, follow no coverage or non-formulary policies as applicable (CP.PMN.255 or CP.PMN.16)
- Off-label review: If requested use not listed and no recent label change applies, refer to off-label use policy CP.PMN.53
CONTINUED COVERAGE CRITERIA
Continued coverage is authorized when ALL of the following are met for any approved indication.
Continued Therapy
Enrollment/previous approval
- Previously met initial criteria: Member currently receiving medication via Centene benefit or has previously met initial approval criteria
- Continuity of care: Member is currently receiving medication and enrolled in a state/product with continuity of care regulations
Refer to state specific addendums CC.PHARM.03A and CC.PHARM.03B
- Response: Member is responding positively to therapy
- Dose increase limit: If request is for a dose increase, new dose does not exceed oral suspension packet of 3.75 grams (1 packet) per day<= 3.75 g/day
Contraindications / Not Medically Necessary
Not covered when the following contraindications are present
Contraindications
- Serum triglycerides > 500 mg/dL
- History of hypertriglyceridemia-induced pancreatitis
- History of bowel obstruction
Non-FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety in accordance with the Off-Label Use Policy CP.PMN.53. Approval decisions for such requests will follow the criteria and documentation standards described in that off‑label policy.
A history of bowel obstruction is listed as a contraindication and exclusion for colesevelam therapy. Requests for WelChol (colesevelam) in members with a documented history of bowel obstruction are not authorized.
Uses that are non‑FDA approved and that lack sufficient documentation of efficacy and safety per the Off‑Label Use Policy CP.PMN.53 are considered not authorized under this policy.
Colesevelam is contraindicated in members with significantly elevated triglycerides. Specifically, use is not appropriate when current serum triglycerides exceed 500 mg/dL or in members with a history of hypertriglyceridemia‑induced pancreatitis; such requests are not authorized.
Coding & Lab Thresholds
Provider Actions & Documentation Requirements
Prior authorization required with full supporting documentation
Prior authorization is required for WelChol packets for suspension. The request must include documentation of the indication, the member's age, prior therapy trials (as applicable to the indication), relevant laboratory values (including current serum triglycerides within the last 3 months), and justification for use of suspension packets such as inability to swallow tablets or clinically significant adverse effects to tablets.
- Documentation must show indication and age (e.g., Age ≥ 10 years for primary hyperlipidemia; Age ≥ 18 years for T2DM).
- Include prior therapy trial details (see required prior trials block) and recent labs (serum triglycerides within 3 months).
- Provide justification for suspension packets (inability to swallow pills or significant adverse effects to tablets).
Document formulation and exact dosing requested
Document the specific formulation and dosing requested: the oral suspension packet dosing (3.75 g PO once daily; packet maximum 3.75 g/day) and availability of the 625 mg tablet should be noted in the request.
- Oral suspension packet: 3.75 g PO once daily (limit 1 packet / 3.75 g per day).
- Tablet product available: 625 mg strength — document if tablets were tried or are not an option.
Document prior trials (cholestyramine, statin, or triple diabetic regimen)
Provide evidence of required prior therapeutic trials before approval: for primary hyperlipidemia this includes failure of cholestyramine powder for suspension at up to maximally indicated doses for ≥ 3 months and failure of ≥ 3 months of adherent statin therapy unless contraindicated; for T2DM provide failure of an adherent triple anti‑diabetic regimen including metformin plus agents from the listed classes for ≥ 3 months unless contraindicated.
- Primary hyperlipidemia: cholestyramine powder trial (≥ 3 months) and statin trial (≥ 3 months) unless contraindicated or intolerant.
- Type 2 diabetes mellitus: triple regimen including metformin (plus GLP-1 RA, SGLT-2 inhibitor, DPP-4 inhibitor, TZD, or basal insulin) for ≥ 3 months unless contraindicated or intolerant.
Document statin context and any statin contraindications
When sequencing therapy with statins, reference the policy appendices for statin intensity categories and statin contraindications; document if statins were contraindicated per Appendix E so that colesevelam sequencing is justified.
- Appendix D lists high, moderate, and low intensity statins for context on prior statin therapy.
- Appendix E lists statin contraindications (e.g., decompensated liver disease, pregnancy, prior statin-related liver injury or rhabdomyolysis) — document any such contraindication if applicable.
Required clinical documentation to support approval
Submit supporting clinical documentation with the prior authorization: office chart notes, recent laboratory results (including serum triglycerides within the last 3 months and HbA1c for T2DM), and records of prior medication trials or intolerances to demonstrate the member meets all approval criteria.
- For T2DM: include HbA1c within past 3 months (≥ 6.5%) when applicable.
- Include dates, durations, and adherence evidence for prior trials (e.g., ≥ 3 months duration).
- Provide documentation of inability to swallow tablets or clinically significant adverse effects to tablets if requesting suspension packets.
Include prescribing information and references
Use the cited references and the Welchol Prescribing Information (2020) as supporting documentation for dosing, indications, and safety when submitting the request.
- Welchol Prescribing Information (Daiichi Sankyo, July 2020) is referenced in the policy for dosing and safety details.
Confirm triglycerides ≤ 500 mg/dL and absence of contraindications
Do not request or expect approval if the member's current serum triglyceride concentration exceeds 500 mg/dL or if there is a history of hypertriglyceridemia‑induced pancreatitis or other listed contraindications; document recent triglyceride level to confirm it is ≤ 500 mg/dL.
- Policy requires current (within last 3 months) serum triglycerides do not exceed 500 mg/dL for initial approval.
- Appendix C lists serum triglyceride concentrations > 500 mg/dL as a contraindication.
Contraindications present = denial risk
Requests that include contraindications such as serum triglycerides > 500 mg/dL or a history of hypertriglyceridemia‑induced pancreatitis are contraindicated and may be denied; ensure these conditions are ruled out and documented prior to submission.
- Appendix C and policy contraindications identify triglycerides > 500 mg/dL and history of hypertriglyceridemia‑induced pancreatitis as grounds for denial.
- History of bowel obstruction is also a listed contraindication and may result in denial.
Background
Colesevelam (WelChol) is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce LDL‑C in adults with primary hyperlipidemia and in certain pediatric patients with familial hypercholesterolemia (HeFH), and to improve glycemic control in adults with type 2 diabetes mellitus. Product forms include a 3.75 g oral suspension packet (administered once daily) and a 625 mg tablet; dosing and safety details are available in the WelChol prescribing information referenced in the policy.
Definitions
Initial Therapy Criteria
INITIAL THERAPY CRITERIA
Initial approval criteria by indication.
Primary Hyperlipidemia Initial
- Product: Welchol packet for suspension requested
- Indication: Prescribed for lipid lowering
- Age >= 10 years
- Swallowing/Tablet intolerance: Documentation of inability to swallow pills or clinically significant adverse effects to Welchol tablets
- Cholestyramine failure: Failure of cholestyramine powder for suspension at maximally indicated doses for >= 3 months unless contraindicated>= 3 months
- Statin failure: Failure of >= 3 months adherent statin therapy unless contraindicated>= 3 months
- Triglyceride limit: Current triglycerides <= 500 mg/dL<= 500 mg/dL
- Dose limit: Dose <= 3.75 g/day (1 packet)<= 3.75 g/day
Type 2 Diabetes Initial
- Product: Welchol packet for suspension requested
- Diagnosis: Type 2 diabetes mellitus
- Age >= 18 years
- HbA1c >= 6.5% within past 3 months>= 6.5% within 3 months
- Triple regimen failure: Failure of adherent use of a triple anti-diabetic regimen including metformin plus agents from specified classes for >= 3 months unless contraindicated>= 3 months
metformin required in regimen
- Triglyceride limit: Current triglycerides <= 500 mg/dL<= 500 mg/dL
- Dose limit: Dose <= 3.75 g/day (1 packet)<= 3.75 g/day
Initial therapy dosing and formulations
Product dosing and availability for initiation.
Continuation Criteria
CONTINUATION CRITERIA
Continued therapy requirements for all indications
Continued Therapy Nodes
Eligibility
- Previously approved or current through Centene: Member currently receiving medication via Centene benefit or previously met initial criteria
- State continuity: Member currently receiving medication and enrolled in state/product with continuity of care regs
See CC.PHARM.03A and CC.PHARM.03B
- Clinical response: Member is responding positively to therapy
- Dose limit: Dose increase does not exceed 3.75 g/day<= 3.75 g/day
Step Therapy Requirements
| Step | Required trial(s) (use at maximally indicated doses unless contraindicated or adverse effects) | Minimum duration / notes |
|---|---|---|
| 1 | ||
| Failure of cholestyramine powder for suspension (granules) — trial at up to maximally indicated doses (see Appendix B therapeutic alternatives for dosing) | ||
| >= 3 months for each agent unless contraindicated or clinically significant adverse effects |
| Appendix | Content | Clinical relevance for sequencing |
|---|---|---|
| Appendix B: Therapeutic Alternatives | ||
| Lists alternative bile acid sequestrants (e.g., colestipol, cholestyramine) and antidiabetic agents (metformin, GLP‑1 RA, SGLT‑2 inhibitors, DPP‑4 inhibitors) with dosing regimens and maximum doses. | ||
| Provides agents to try prior to WelChol per indication and shows dosing references to confirm trials were at maximally indicated doses. | ||
| Appendix D: Statin Intensity Classification | ||
| Classifies statins into high, moderate, and low intensity (e.g., atorvastatin 40–80 mg, rosuvastatin 20–40 mg as high intensity; lists lower-intensity equivalents). | ||
| Helps determine whether prior statin therapy met intensity expectations when sequencing lipid-lowering therapies before colesevelam. | ||
| Appendix E: Statin Contraindications | ||
| Identifies contraindications to statin use (decompensated liver disease, confirmed statin-induced acute liver injury or rhabdomyolysis, pregnancy/lactation, immune-mediated hypersensitivity to statins). | ||
| When statins are contraindicated per this appendix, sequencing may allow colesevelam without an adequate statin trial; documents rationale for deviation from standard step requirements. |
Quantity Limits
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.